More evidence that the future of cancer research is less about where cancer originates in the body and more about its biomarkers was presented by Vivek Subbiah, M.D., from MD Anderson Cancer Center at the American Assoc. for Cancer Research’s April 2021 meeting.
A study sponsored by Lilly, Inc., showed Retevmo® (selpercatinib) shrunk tumors in 47% of patients with RET fusion-positive cancers originating from different sites in the body other than the lung and the thyroid. Lilly is working to develop Retevmo® as a tissue agnostic drug to treat all RET fusion-positive cancers regardless of their location, David Hyman, M.D., Lilly’s chief medical officer of oncology, said in an interview.